Please ensure Javascript is enabled for purposes of website accessibility

Why Teva Pharmaceutical Industries Ltd. Stock Jumped Today

By George Budwell - Jul 27, 2015 at 10:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Teva Pharmaceutical Industries Ltd. saw its shares jump by 11% in early morning trading today. Here's why.

What: Shares of the generic drugmaker Teva Pharmaceutical Industries Ltd. (TEVA 1.08%) rose by 11% in early morning trading after the company announced that it plans on buying Allergan's (AGN) generic drug business in a cash and stock deal worth a reported $40.5 billion. After striking this deal with Allergan, Teva also decided to drop its $40 billion hostile takeover bid for rival generic drug giant Mylan (MYL)

So what: This deal would make Teva one of the largest pharmaceutical companies in the world in terms of sales, and help to significantly diversify its revenue base away from the multiple sclerosis drug Copaxone that has historically composed over half of the company's revenues. Copaxone is now facing generic competition, which was expected to cut deeply into Teva's top and bottom-lines going forward. 

Now what: The Street is applauding this agreement because it gives Teva more than 1,000 new products, and is estimated to result in cost savings of approximately $1.4 billion over the next three years. As a result, we should see Teva's diluted EPS growth rate soar into the high double digits once the deal closes. By contrast, Teva was on track to post essentially flat growth in terms of its earnings next year, and the years ahead were looking especially lean for the drugmaker given the threat of generics to its main revenue source. All told, this acquisition looks like a great move for Teva's shareholders, and should set the company up for a long period of sustainable growth.  

 

George Budwell has no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Allergan plc Stock Quote
Allergan plc
AGN
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$11.21 (1.08%) $0.12
Viatris Inc. Stock Quote
Viatris Inc.
MYL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.